Alyeska Investment Group
CGTX icon

Alyeska Investment Group’s Cognition Therapeutics CGTX Stock Holding History

Alyeska Investment Group’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-102,095
Closed -$138K – 607
2025
Q3 		$138K Buy
+102,095
New +$139K ﹤0.01% 577
2025
Q1 		– Sell
-500,000
Closed -$351K – 529
2024
Q4 		$351K Hold
500,000
– – ﹤0.01% 527
2024
Q3 		$234K Hold
500,000
– – ﹤0.01% 502
2024
Q2 		$830K Hold
500,000
– – ﹤0.01% 474
2024
Q1 		$910K Buy
+500,000
New +$1.03M 0.01% 417

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.17B AUM 42.44% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.47B AUM 18.73% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return

Alyeska Investment Group's CGTX Position: Q4 2025 in Review

Alyeska Investment Group sold out of Cognition Therapeutics (CGTX) in Q4 2025, closing a stake of 102,095 shares — an estimated $138K sold.

Alyeska Investment Group first reported a position in CGTX in Q1 2024 and held it in 5 quarters. The position peaked at $910K in Q1 2024. 78 funds tracked by Wall St. Rank hold CGTX as of Q4 2025.

  • Alyeska Investment Group reported no remaining Cognition Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Alyeska Investment Group sold 102,095 Cognition Therapeutics shares in Q4 2025, an estimated $138K.
  • Alyeska Investment Group first reported a position in Cognition Therapeutics in Q1 2024 and held it in 5 quarters.
  • Alyeska Investment Group's Cognition Therapeutics position peaked at $910K in Q1 2024.
  • 78 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q4 2025.

Based on Alyeska Investment Group's 13F filing for Q4 2025, filed 13 Feb 2026.